Interleukin-17A Inhibitor
Izokibep for Uveitis
This trial tests izokibep, a small protein, in patients with severe eye inflammation who need high-dose steroids. By blocking certain molecules, izokibep aims to reduce inflammation and potentially lower the need for steroids.
Dexamethasone Insert vs Steroid Drops for Postoperative Inflammation
This trial will compare the efficacy of two treatments for inflammation following vitreoretinal surgery. One group will receive a dexamethasone insert and the other group will receive topical steroid drops.
Popular Filters
Trials With No Placebo
Corticosteroid
Fluocinolone Acetonide Implant for Posterior Uveitis
This trial will test a new, long-term treatment for uveitis, an inflammation of the eye. The goal is to see if the implant is safe and effective for patients who have responded to steroid therapy in the past.
Comprehensive Sequencing
Deep Sequencing Test for Intraocular Infections
This trial is designed to compare the effectiveness of a new deep sequencing test for intraocular infections versus the current standard of care test. Patients who receive the new test will be compared to those who do not to see if there are improved outcomes.
Frequently Asked Questions
Introduction to uveitis
What are the top hospitals conducting uveitis research?
When it comes to cutting-edge clinical trials in the field of uveitis, several hospitals across the United States are making significant strides. Texas Retina Associates, located in Plano, has emerged as a leader with three active uveitis trials and a total of three completed trials dedicated to this condition. The hospital first delved into uveitis research in 2022, marking an exciting milestone in their efforts to advance treatment options for patients. Meanwhile, all the way on the west coast, the University of California, San Francisco has been actively involved in studying uveitis since 2015. With two ongoing trials and four completed studies under their belt, they continue to push boundaries at one of the nation's top medical institutions.
Furthermore highlighting innovation is Seattle Children's Hospital known for its groundbreaking pediatric care; here they conducted pioneering investigation regarding Uveitis cases way back until 2020 and currently possess two active endeavors towards same goal.Children's Hospital of Philadelphia also made notable contributions by initiating examinations tailored specifically towards understanding Uveitistwo years ago sharing similar numbers with Seattle children’s hospital.Currently both Tennessee Retina located at Nashville alongside Children’s National Hospital basedin Washington D.C.have initiated investigations revolving aroundnovel therapeutic approaches against Uvritis individually holding two respective investigations each; while Tennessee retina tookofficiating steps only recent yearin2019Children’s national hopitalhas held prior investigatory tests throughout past decade till now.
These remarkable hospitals demonstrate not only their commitment to advancing our knowledge and treatment options for uveitis but also their dedication to patient care. Their tireless efforts contribute significantly to improving outcomes for individuals affected by this complex eye condition nationwide
Which are the best cities for uveitis clinical trials?
When it comes to uveitis clinical trials, several cities in the United States are at the forefront of research and innovation. Nashville, Tennessee leads with 7 active trials investigating treatments like Adalimumab (ADA), Brepocitinib, and Abatacept Injection. Plano and Bellaire in Texas join the ranks with 6 ongoing studies each, focusing on Brepocitinib, Yutiq 0.18 MG Drug Implant, Izokibep, and other potential therapeutic options. San Francisco in California also contributes significantly with 6 active trials exploring Izokibep, Metagenomic Deep Sequencing (MDS), Abatacept Injection among others. Salt Lake City in Utah follows closely behind with 5 active trials examining treatments including Brepocitinib and Adalimumab (ADA). These cities offer individuals affected by uveitis access to cutting-edge clinical trials that may shape future treatment approaches for this condition.
Which are the top treatments for uveitis being explored in clinical trials?
Exciting developments are underway in the exploration of new treatments for uveitis, a condition that affects the eye. Leading the charge is brepocitinib, yutiq 0.18 MG Drug Implant, izokibep, and metagenomic deep sequencing (MDS). Each treatment shows promise with one active trial dedicated to uveitis and first listed in 2022. These innovative approaches offer hope for improved management of this challenging condition and may pave the way towards better outcomes for patients.
What are the most recent clinical trials for uveitis?
Recent clinical trials have provided promising insights into the treatment of uveitis, a condition that affects the eye's middle layer. One such study investigated ESK-001 Dose Level 1, which showed potential in managing uveitis symptoms during Phase 2 trials. Another trial assessed the effectiveness of high-dose UME - 6 drops OCS-01 as a possible treatment option for uveitis patients. Brepocitinib, an experimental drug currently in Phase 2 trials, also holds promise as a potential therapy for this condition. Additionally, Yutiq 0.18 MG Drug Implant has shown positive results in its Phase 3 trial and may offer new possibilities for long-term uveitis management. Finally, Izokibep is being evaluated in Phase 2 studies to determine its efficacy against uveitis-related inflammation and complications. These ongoing investigations bring hope to individuals suffering from this challenging ocular disease.
What uveitis clinical trials were recently completed?
Several recent clinical trials have made significant strides in the field of uveitis research. In January 2022, Affibody concluded its trial for Izokibep, a potential treatment option. Equally noteworthy is the completion of the TRS01 trial by Tarsier Pharma in September 2021. Although not as recent, it's worth mentioning that Eye Pharma completed their Norflo Oro trial back in December 2018. These advancements demonstrate ongoing efforts to advance our understanding and develop effective therapies for uveitis patients.